Garuda Therapeutics

About

Garuda Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company specializes in developing off-the-shelf hematopoietic stem cell (HSC) therapies, aiming to eliminate the need for donor or patient cells in blood stem cell transplants. Garuda focuses on creating self-renewing, HLA-compatible, and transgene-free blood stem cells, which provide immediate access to therapies for patients, particularly addressing donor matching challenges. The company has raised a total of $184.12 million, including significant funding rounds to support its innovative platform. Garuda's lead product, now branded as ST-101, includes Prime HSCs™ and Prime HPCs™ designed for curative blood and immune restoration across a wide range of conditions, including hematologic malignancies and autoimmune diseases. The proprietary technology enables durable engraftment and immune reconstitution, reducing risks associated with traditional transplants. Garuda Therapeutics is committed to advancing regenerative medicine and improving patient outcomes through its cutting-edge therapies.